Search
Etomidate
go.drugbank.com/drugs/DB00292ApprovedInvestigationalIt has been proposed as an induction anesthetic.
Idarubicin
go.drugbank.com/drugs/DB01177ApprovedInvestigationalAn orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Products: IDARALEM RUChlorphenoxamine
go.drugbank.com/drugs/DB09007ApprovedWithdrawnIt is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.
Pyrimethamine
go.drugbank.com/drugs/DB00205ApprovedInvestigationalVet approvedOne of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.
Sulfabenzamide
go.drugbank.com/drugs/DB09355ApprovedWithdrawnSulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide as a topical intravaginal antibacterial preparation.
IGN301
go.drugbank.com/drugs/DB05117ExperimentalIGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y.
ALMB-0166
go.drugbank.com/drugs/DB17937InvestigationalIt was granted FDA orphan designation in November 2018.[L47067]
XP12B
go.drugbank.com/drugs/DB04928InvestigationalIt was granted Fast Track status for this indication by the FDA in November 2004.
Didesmethylrocaglamide
go.drugbank.com/drugs/DB15496ExperimentalDidesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their inse...
Dexrazoxane
go.drugbank.com/drugs/DB00380ApprovedInvestigationalWithdrawnAn antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. … [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.